$MBRX
Moleculin Biotech, Inc.

2021 Q1 Form 10-K Financial Statement

#000143774921006940 Filed on March 24, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 2019 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.940M $6.790M $1.560M
YoY Change 7.18% 7.61% 13.87%
% of Gross Profit
Research & Development $4.105M $12.76M $3.200M
YoY Change 28.04% 15.84% 9.22%
% of Gross Profit
Depreciation & Amortization $44.00K $200.0K $50.00K
YoY Change -4.35% 0.5% 25.0%
% of Gross Profit
Operating Expenses $6.088M $19.74M $4.810M
YoY Change 20.27% 12.66% 10.83%
Operating Profit -$6.088M -$19.74M
YoY Change 20.27% 12.66%
Interest Expense $1.630M $2.360M $1.010M
YoY Change -57.66% -42.16% -35.67%
% of Operating Profit
Other Income/Expense, Net $9.000K $28.00K $10.00K
YoY Change 80.0% 86.67% -150.0%
Pretax Income -$4.450M -$17.36M -$3.800M
YoY Change 267.77% 29.19% 36.2%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.445M -$17.40M -$3.800M
YoY Change 267.66% 31.82% 36.2%
Net Earnings / Revenue
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$204.0K -$1.762M -$498.0K
COMMON SHARES
Basic Shares Outstanding 28.44M 45.73M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $86.29M $15.17M $10.74M
YoY Change 640.69% 41.25% 50.63%
Cash & Equivalents $86.30M $15.17M $10.74M
Short-Term Investments
Other Short-Term Assets $1.730M $1.860M $529.0K
YoY Change 181.3% -32.12% -37.02%
Inventory
Prepaid Expenses $2.749M
Receivables $1.000K
Other Receivables
Total Short-Term Assets $88.02M $17.20M $13.48M
YoY Change 538.42% 27.6% 69.1%
LONG-TERM ASSETS
Property, Plant & Equipment $438.0K $690.0K $316.0K
YoY Change 61.62% 15.0% -31.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.77M $11.83M $11.75M
YoY Change 0.68% 0.6% 1.21%
TOTAL ASSETS
Total Short-Term Assets $88.02M $17.20M $13.48M
Total Long-Term Assets $11.77M $11.83M $11.75M
Total Assets $99.78M $29.03M $25.24M
YoY Change 291.74% 15.02% 28.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.928M $1.130M $2.153M
YoY Change 59.87% -47.44% 72.79%
Accrued Expenses $2.650M $1.710M $1.417M
YoY Change 30.61% 29.55% -42.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.578M $2.920M $3.570M
YoY Change 41.51% -18.21% -7.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.690M $8.350M $6.090M
YoY Change -3.74% 37.11% 322.92%
Total Long-Term Liabilities $6.690M $8.350M $6.090M
YoY Change -3.74% 37.11% 322.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.578M $2.920M $3.570M
Total Long-Term Liabilities $6.690M $8.350M $6.090M
Total Liabilities $11.27M $11.27M $9.664M
YoY Change 10.69% 16.67% 81.89%
SHAREHOLDERS EQUITY
Retained Earnings -$61.40M -$39.56M
YoY Change 50.49% 50.1%
Common Stock $149.8M $55.10M
YoY Change 167.22% 35.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $88.52M $17.76M $15.57M
YoY Change
Total Liabilities & Shareholders Equity $99.78M $29.03M $25.24M
YoY Change 291.74% 15.02% 28.85%

Cashflow Statement

Concept 2021 Q1 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$4.445M -$17.40M -$3.800M
YoY Change 267.66% 31.82% 36.2%
Depreciation, Depletion And Amortization $44.00K $200.0K $50.00K
YoY Change -4.35% 0.5% 25.0%
Cash From Operating Activities -$3.600M -$17.80M -$4.680M
YoY Change -16.28% 3.49% 50.48%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $376.0K -$10.00K
YoY Change -100.0% 623.08% -91.67%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 -$374.0K -$10.00K
YoY Change -100.0% 633.33% -91.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $74.69M $22.56M
YoY Change 1311.55% 16.94%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $74.75M $22.55M 0.000
YoY Change 1312.74% 8.13% -100.0%
NET CHANGE
Cash From Operating Activities -$3.600M -$17.80M -4.680M
Cash From Investing Activities $0.00 -$374.0K -10.00K
Cash From Financing Activities $74.75M $22.55M 0.000
Net Change In Cash $71.12M $4.438M -4.690M
YoY Change 7681.18% 23.24% 221.23%
FREE CASH FLOW
Cash From Operating Activities -$3.600M -$17.80M -$4.680M
Capital Expenditures $0.00 $376.0K -$10.00K
Free Cash Flow -$3.600M -$18.18M -$4.670M
YoY Change -16.32% 5.36% 56.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
178000 USD
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28444425
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
474000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
284000 USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.001 pure
CY2020Q4 us-gaap Liabilities
Liabilities
11271000 USD
CY2020Q4 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
65000 USD
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11536720
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11536720
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7621338
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7621338
CY2020Q4 mbrx Number Of Core Drug Technologies
NumberOfCoreDrugTechnologies
3 pure
CY2020Q4 mbrx Number Of Drug Candidates
NumberOfDrugCandidates
4 pure
CY2020Q4 mbrx Number Of Drugs In Clinical Trials
NumberOfDrugsInClinicalTrials
5 pure
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2020 mbrx Licensing Agreement Term
LicensingAgreementTerm
P3Y
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15173000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10735000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2025000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2749000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
17198000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
13484000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
483000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
316000 USD
CY2020Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2019Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
202000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
287000 USD
CY2020Q4 us-gaap Assets
Assets
29031000 USD
CY2019Q4 us-gaap Assets
Assets
25235000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1129000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2153000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1791000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1417000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2920000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3570000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
159000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
276000 USD
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
8192000 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5818000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
9664000 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
69000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
46000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
74671000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
55055000 USD
CY2020Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
129000 USD
CY2019Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
-0 USD
CY2019Q4 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
31000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56916000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39561000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17760000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15571000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29031000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25235000 USD
CY2020 us-gaap Revenues
Revenues
0 USD
CY2019 us-gaap Revenues
Revenues
0 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12757000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11013000 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6785000 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6312000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
199000 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
19742000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
17524000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-19742000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-17524000 USD
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2346000 USD
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4062000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
28000 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000 USD
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
13000 USD
CY2019 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
13000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17355000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13434000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-229000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17355000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-13205000 USD
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.76
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.95
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9845685
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6786901
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17355000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-13205000 USD
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
34000 USD
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17321000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13209000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17355000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-13205000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
199000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1680000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1537000 USD
CY2020 mbrx Common Stock Issued For License Rights Under License Agreement
CommonStockIssuedForLicenseRightsUnderLicenseAgreement
0 USD
CY2019 mbrx Common Stock Issued For License Rights Under License Agreement
CommonStockIssuedForLicenseRightsUnderLicenseAgreement
490000 USD
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-6000 USD
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000 USD
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2346000 USD
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4062000 USD
CY2020 mbrx Operating Lease Noncash Expense Net Of Sublease Receipts
OperatingLeaseNoncashExpenseNetOfSubleaseReceipts
85000 USD
CY2019 mbrx Operating Lease Noncash Expense Net Of Sublease Receipts
OperatingLeaseNoncashExpenseNetOfSubleaseReceipts
-14000 USD
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-724000 USD
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1909000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1024000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
907000 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
259000 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1140000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17771000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17198000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
376000 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
52000 USD
CY2020 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
2000 USD
CY2019 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
1000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-374000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51000 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000 USD
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5000 USD
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1557000 USD
CY2020 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
17000 USD
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
-0 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22561000 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19292000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22549000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20854000 USD
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34000 USD
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-4000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4438000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3601000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10735000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7134000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15173000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10735000 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
1000 USD
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
24000 USD
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
19000 USD
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
22000 USD
CY2020 mbrx Common Stock Subscription Receivable Issued
CommonStockSubscriptionReceivableIssued
129000 USD
CY2019 mbrx Common Stock Subscription Receivable Issued
CommonStockSubscriptionReceivableIssued
0 USD
CY2020 mbrx Shares Issued In Lieu Of Cash
SharesIssuedInLieuOfCash
0 USD
CY2019 mbrx Shares Issued In Lieu Of Cash
SharesIssuedInLieuOfCash
490000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
14272000 USD
CY2019 mbrx Stock Issued During Period Value License Rights
StockIssuedDuringPeriodValueLicenseRights
490000 USD
CY2019 mbrx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
4731000 USD
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1537000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-13205000 USD
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15571000 USD
CY2020 mbrx Subscription Of Common Stock Value
SubscriptionOfCommonStockValue
0 USD
CY2020 mbrx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
9000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1680000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-13200000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17355000 USD
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
34000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17760000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
436000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17400000 USD
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-17000 USD
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><b>Use of Estimates -</b> The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors <em style="font: inherit;"> may </em>affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often <em style="font: inherit;"> may </em>yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process <em style="font: inherit;"> may </em>result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><b> </b></p>
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17800000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17200000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56900000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15200000 USD
CY2019Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
10000 USD
CY2020Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
1000 USD
CY2020Q4 mbrx Accrued Clinical Activities Current
AccruedClinicalActivitiesCurrent
281000 USD
CY2019Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
1000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2025000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2749000 USD
CY2020Q4 mbrx Vendor Prepayments And Deposits
VendorPrepaymentsAndDeposits
1281000 USD
CY2019Q4 mbrx Vendor Prepayments And Deposits
VendorPrepaymentsAndDeposits
1857000 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
579000 USD
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
352000 USD
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
164000 USD
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
529000 USD
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0 USD
CY2020 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2019Q4 mbrx Accrued Clinical Activities Current
AccruedClinicalActivitiesCurrent
93000 USD
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
99000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1791000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1417000 USD
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3600000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2000000.0
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
426000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11100000 USD
CY2020Q4 mbrx Accrued Chemistry Manufacturing And Control Costs Current
AccruedChemistryManufacturingAndControlCostsCurrent
460000 USD
CY2019Q4 mbrx Accrued Chemistry Manufacturing And Control Costs Current
AccruedChemistryManufacturingAndControlCostsCurrent
49000 USD
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2843284
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1500000 USD
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1794032
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1300000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
272000 USD
CY2020Q4 mbrx Accrued License Fees And Sponsored Research Agreements
AccruedLicenseFeesAndSponsoredResearchAgreements
166000 USD
CY2019Q4 mbrx Accrued License Fees And Sponsored Research Agreements
AccruedLicenseFeesAndSponsoredResearchAgreements
201000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
84000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
164000 USD
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
78000 USD
CY2020Q4 mbrx Shares Authorized
SharesAuthorized
105000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
224964
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1680000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1537000 USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
639353
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
9.53
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.55
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
267468
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.96
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.66
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3334
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
5.34
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.36
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
903487
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
8.19
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.24
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
364852
CY2020Q4 mbrx Sharebased Compensation Arrangement By Sharebased Payment Award Option Nonvested Exercisable Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionNonvestedExercisableWeightedAverageGrantDateFairValue
11.23
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.39
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2020Q4 mbrx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Aggregate Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateFairValue
1300000 USD
CY2020 mbrx Effective Income Tax Rate Reconciliation Stock Warrant Costs
EffectiveIncomeTaxRateReconciliationStockWarrantCosts
493000 USD
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
3645000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
2773000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
44000 USD
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-229000 USD
CY2020 mbrx Deferred Tax Assets Valuation Allowance Releases
DeferredTaxAssetsValuationAllowanceReleases
0 USD
CY2019 mbrx Deferred Tax Assets Valuation Allowance Releases
DeferredTaxAssetsValuationAllowanceReleases
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13867000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9418000 USD
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0 USD
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-229000 USD
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-229000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9418000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5855000 USD
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4449000 USD
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3563000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.003 pure
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-4000 USD
CY2019 mbrx Effective Income Tax Rate Reconciliation Permanent Ptr Items
EffectiveIncomeTaxRateReconciliationPermanentPtrItems
107000 USD
CY2019 mbrx Effective Income Tax Rate Reconciliation Permanent Ptr Items Percent
EffectiveIncomeTaxRateReconciliationPermanentPtrItemsPercent
0.008 pure
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
12000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.000 pure
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.001 pure
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
-34000 USD
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
6000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.000 pure
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
11000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.003 pure
CY2020 mbrx Effective Income Tax Rate Reconciliation Stock Warrant Costs Percent
EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent
0.028 pure
CY2019 mbrx Effective Income Tax Rate Reconciliation Stock Warrant Costs
EffectiveIncomeTaxRateReconciliationStockWarrantCosts
853000 USD
CY2019 mbrx Effective Income Tax Rate Reconciliation Stock Warrant Costs Percent
EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent
0.065 pure
CY2019 mbrx Effective Income Tax Rate Reconciliation Other Permanent Difference
EffectiveIncomeTaxRateReconciliationOtherPermanentDifference
-72000 USD
CY2019 mbrx Effective Income Tax Rate Reconciliation Other Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent
-0.005 pure
CY2020 mbrx Effective Income Tax Rate Reconciliation Permanent Ptr Items
EffectiveIncomeTaxRateReconciliationPermanentPtrItems
361000 USD
CY2020 mbrx Effective Income Tax Rate Reconciliation Permanent Ptr Items Percent
EffectiveIncomeTaxRateReconciliationPermanentPtrItemsPercent
0.021 pure
CY2020 mbrx Effective Income Tax Rate Reconciliation Other Permanent Difference
EffectiveIncomeTaxRateReconciliationOtherPermanentDifference
-63000 USD
CY2020 mbrx Effective Income Tax Rate Reconciliation Other Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent
-0.004 pure
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0 pure
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
229000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.017 pure
CY2020 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
-48000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
-0.003 pure
CY2019 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
-33000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
-0.003 pure
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0 pure
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-38000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.003 pure
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-4450000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.256 pure
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-3563000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.270 pure
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 USD
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-229000 USD
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.017 pure
CY2020Q4 mbrx Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
4158000 USD
CY2019Q4 mbrx Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
2991000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
7982000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
5376000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
48000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
19000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
126000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
51000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
670000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
405000 USD
CY2020Q4 mbrx Deferred Tax Assets Rou Liability
DeferredTaxAssetsROULiability
58000 USD
CY2019Q4 mbrx Deferred Tax Assets Rou Liability
DeferredTaxAssetsROULiability
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9451000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
880000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
609000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
13922000 USD
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
134000 USD
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
74000 USD
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13867000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9418000 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
55000 USD
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
33000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
12000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
33000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
43000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
-0 USD
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
55000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
33000 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13900000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9400000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
72000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
38000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
46000 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
34000 USD
CY2020 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0 USD
CY2019 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0 USD
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0 USD
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
118000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
72000 USD
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
116000 USD
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
60000 USD
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
17000 USD
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
43000 USD
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
29000 USD
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
27000 USD
CY2020 us-gaap Lease Cost
LeaseCost
162000 USD
CY2019 us-gaap Lease Cost
LeaseCost
130000 USD
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
321000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
138000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
105000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
56000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
10000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
309000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
32000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
277000 USD
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096 pure
CY2020 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
750000 USD
CY2020 mbrx Payments For Research And Development Agreement
PaymentsForResearchAndDevelopmentAgreement
1000000.0 USD
CY2019Q2 mbrx Payments For Research And Development Agreement
PaymentsForResearchAndDevelopmentAgreement
1000000.0 USD
CY2018 mbrx Payments For Research And Development Agreement
PaymentsForResearchAndDevelopmentAgreement
1000000.0 USD
CY2020 mbrx Employee Agreements Termination Benefits Provided To Key Employees Aggregate Amount
EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount
900000 USD

Files In Submission

Name View Source Status
0001437749-21-006940-index-headers.html Edgar Link pending
0001437749-21-006940-index.html Edgar Link pending
0001437749-21-006940.txt Edgar Link pending
0001437749-21-006940-xbrl.zip Edgar Link pending
ex_205813.htm Edgar Link pending
ex_205814.htm Edgar Link pending
ex_205815.htm Edgar Link pending
ex_205816.htm Edgar Link pending
ex_205817.htm Edgar Link pending
ex_235706.htm Edgar Link pending
ex_235841.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mbrx-20201231.xsd Edgar Link pending
mbrx-20201231_cal.xml Edgar Link unprocessable
mbrx-20201231_def.xml Edgar Link unprocessable
mbrx-20201231_lab.xml Edgar Link unprocessable
mbrx-20201231_pre.xml Edgar Link unprocessable
mbrx20201231_10k.htm Edgar Link pending
mbrx20201231_10k_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending